InvestorsHub Logo
Followers 4
Posts 187
Boards Moderated 0
Alias Born 05/25/2019

Re: None

Tuesday, 03/31/2020 3:20:09 PM

Tuesday, March 31, 2020 3:20:09 PM

Post# of 426184
Lars Ekman - common denominator between Elan and Amarin crashes - needs investigation

Lars Ekman, MD, Ph.D., joined Amarin as a Non-Executive Director in November 2008 and was named Amarin's Chairman of the Board of Directors effective January 2014. With more than 28-years of experience in the pharmaceutical industry, Dr. Ekman is an Executive Partner of Sofinnova Ventures. He previously served as Co-Founder and Chief Executive Officer of Cebix Inc, and prior to that he was Executive Vice President and President of Global Research and Development of Elan Corporation plc from January 2001 to December 2007. Prior to joining Elan, he was Executive Vice President, Research and Development at Schwarz Pharma AG from February 1997 to December 2000, and was previously employed in a variety of senior scientific and clinical functions at Pharmacia, now Pfizer. He serves as Executive Chairman of Sophiris Bio Inc. (formerly Protox Therapeutics) as well as Chairman of Prothena Biosciences. Dr. Ekman also sits on the Board of Directors of Cebix Inc., InterMune, and Ocera Therapeutics. Dr. Ekman is a board certified surgeon with a PhD in experimental biology and has held several clinical and academic positions in the United States and Europe. He obtained his PhD and MD from the University of Gothenburg, Sweden.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News